BioCentury | Mar 26, 2021
Finance

As valuation swells above $380M, Syncona-backed Gyroscope draws $148M series C, mulls listing

Gene therapy developer Gyroscope has another $148 million to fuel further clinical testing of its lead program for age-related macular degeneration — and the Syncona-backed, U.K.-based company could...
BioCentury | Mar 16, 2021
Product Development

March 16 COVID Quick Takes: FDA launches adverse events dashboard; plus Kintor, Boehringer, Apeiron, Moderna and more

FDA launched an FDA Adverse Event Reporting System (FAERS) public dashboard for COVID-19 drugs and biologics with emergency use authorization (EUA). The launch comes as EMA’s Pharmacovigilance Risk Assessment...
BioCentury | Feb 9, 2021
Product Development

Feb. 8 Quick Takes: FDA approves TG’s lymphoma therapy; plus uniQure, Astellas, BMS, Viiv, Avrobio and Veru

...the company announced 12-month data from the second Fabry disease patient in the Phase II FAB-GT...
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

...DNuance Biotech raised $181 million in a series D round led by RTW Investments and GT...
BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

The launch of Purespring Therapeutics marks the next phase of Syncona’s strategy in moving gene therapy from targeting rare monogenic diseases to more complex, highly prevalent settings. On Thursday, Syncona Ltd. (LSE:SYNC) launched its sixth...
BioCentury | Jun 10, 2020
Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

...Biogen Inc. (NASDAQ:BIIB), Bristol Myers Squibb Co. (NYSE:BMY), Pfizer Ventures, Invus, Section 32, Samsara BioCapital, GT...
BioCentury | May 28, 2020
Finance

May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys

...A/S, with participation from existing investors Evotec AG (Xetra:EVT), Bristol Myers Squibb Co. (NYSE:BMY) and GT...
BioCentury | May 22, 2020
Finance

Kintor IPO latest sign of Hong Kong’s maturing biotech chapter

On a turbulent day for the Hong Kong stock exchange, shares of oncology company Kintor gained HK$1.35 to HK$21.50 in their first day of trading Friday after the company raised HK$1.9 billion ($240 million) through...
BioCentury | May 14, 2020
Finance

May 13 Quick Takes: MyoKardia raises $551M; plus Legend looks to NASDAQ for IPO and ADC, Travecta, QureBio, Kintor, Lantern, Kiromic

MyoKardia prices follow-on at a premium MyoKardia Inc. (NASDAQ:MYOK) raised $551.3 million late Tuesday through the sale of 5.3 million shares at $105 in a bumped-up offering that stands to be the biggest follow-on of...
BioCentury | Jan 3, 2020
Financial News

Jan. 3 Financial Quick Takes: Black Diamond plots IPO; plus Oxford Nanopore, CF PharmTech, Mygene and Zerun

...by New Alliance Capital. Also participating were new investors CR-CP Life Science Fund, Finnova Capital, GT...
Items per page:
1 - 10 of 183
BioCentury | Mar 26, 2021
Finance

As valuation swells above $380M, Syncona-backed Gyroscope draws $148M series C, mulls listing

Gene therapy developer Gyroscope has another $148 million to fuel further clinical testing of its lead program for age-related macular degeneration — and the Syncona-backed, U.K.-based company could...
BioCentury | Mar 16, 2021
Product Development

March 16 COVID Quick Takes: FDA launches adverse events dashboard; plus Kintor, Boehringer, Apeiron, Moderna and more

FDA launched an FDA Adverse Event Reporting System (FAERS) public dashboard for COVID-19 drugs and biologics with emergency use authorization (EUA). The launch comes as EMA’s Pharmacovigilance Risk Assessment...
BioCentury | Feb 9, 2021
Product Development

Feb. 8 Quick Takes: FDA approves TG’s lymphoma therapy; plus uniQure, Astellas, BMS, Viiv, Avrobio and Veru

...the company announced 12-month data from the second Fabry disease patient in the Phase II FAB-GT...
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

...DNuance Biotech raised $181 million in a series D round led by RTW Investments and GT...
BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

The launch of Purespring Therapeutics marks the next phase of Syncona’s strategy in moving gene therapy from targeting rare monogenic diseases to more complex, highly prevalent settings. On Thursday, Syncona Ltd. (LSE:SYNC) launched its sixth...
BioCentury | Jun 10, 2020
Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

...Biogen Inc. (NASDAQ:BIIB), Bristol Myers Squibb Co. (NYSE:BMY), Pfizer Ventures, Invus, Section 32, Samsara BioCapital, GT...
BioCentury | May 28, 2020
Finance

May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys

...A/S, with participation from existing investors Evotec AG (Xetra:EVT), Bristol Myers Squibb Co. (NYSE:BMY) and GT...
BioCentury | May 22, 2020
Finance

Kintor IPO latest sign of Hong Kong’s maturing biotech chapter

On a turbulent day for the Hong Kong stock exchange, shares of oncology company Kintor gained HK$1.35 to HK$21.50 in their first day of trading Friday after the company raised HK$1.9 billion ($240 million) through...
BioCentury | May 14, 2020
Finance

May 13 Quick Takes: MyoKardia raises $551M; plus Legend looks to NASDAQ for IPO and ADC, Travecta, QureBio, Kintor, Lantern, Kiromic

MyoKardia prices follow-on at a premium MyoKardia Inc. (NASDAQ:MYOK) raised $551.3 million late Tuesday through the sale of 5.3 million shares at $105 in a bumped-up offering that stands to be the biggest follow-on of...
BioCentury | Jan 3, 2020
Financial News

Jan. 3 Financial Quick Takes: Black Diamond plots IPO; plus Oxford Nanopore, CF PharmTech, Mygene and Zerun

...by New Alliance Capital. Also participating were new investors CR-CP Life Science Fund, Finnova Capital, GT...
Items per page:
1 - 10 of 183